MetaCap

SIGA Technologies (SIGA) vs Sol-Gel Technologies (SLGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sol-Gel Technologies (SLGL) has outperformed SIGA Technologies (SIGA) over the past year, gaining 50.5% versus a loss of 58.9%. Over five years, SLGL leads with a -28.4% price change compared with -71.9% for SIGA. Sol-Gel Technologies is the larger company by market cap ($180.6 million vs $172.5 million), about 1.0 times the size.

SIGA Technologies converts more of its revenue into profit, with a net margin of 24.6% versus -31.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SIGA-58.90%SLGL+50.53%
+179%+54%-70%
Nov 21, 20251 yearNov 20, 2026
SIGA-74.08%SLGL-35.62%
+180%+36%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SIGA versus SLGL key metrics
MetricSIGASLGL
Share price$2.40$55.17
Market cap$172.45M$180.63M
1-day change-9.43%+2.02%
YTD return-60.72%+30.92%
1-year return-58.90%+50.53%
5-year return-71.90%-28.44%
P/E ratio (TTM)240.00—
Forward P/E5.45—
EPS (TTM)$0.01$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$94.57M$19.39M
Revenue growth (YoY)-31.82%+68.04%
Net income (latest FY)$23.28M$-6.13M
Gross margin68.59%—
Operating margin25.06%-38.88%
Net margin24.61%-31.60%
52-week high$7.11$97.97
52-week low$2.30$34.47
Distance from 52-week high-66.24%-43.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+35.42%+181.86%
Average volume617.60K47.38K
Shares outstanding71.86M3.27M
Employees4928
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLGL has outperformed SIGA by 109.4 percentage points over the past year.
  • SIGA Technologies is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -31.6 cents for Sol-Gel Technologies.
  • Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -31.82%).

About SIGA Technologies

SIGA stock →

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Sol-Gel Technologies

SLGL stock →

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

SIGA vs SLGL FAQ

Which is bigger, SIGA Technologies or Sol-Gel Technologies?

Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $180.63M compared with $172.45M for SIGA Technologies (SIGA).

Which stock has performed better over the past year, SIGA or SLGL?

SLGL returned +50.53% over the past 12 months, compared with -58.90% for SIGA (price return, excluding dividends). Past performance does not predict future results.

Are SIGA Technologies and Sol-Gel Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons